Public articles linked to the same research event.
arXiv The study presents Andromeda 2, an agentic system that reasons over structured in-house experimental evidence and invokes computational and experimental tools, achieving a 50% high-AUC hit rate for paclitaxel self-emulsifying drug delivery system (SEDDS) development at a matched budget of 96 formulations (versus 17% for Andromeda 1 and 2% for wet-lab DoE) and identifying 12 formulations meeting all four target product profile (TPP) objectives (versus 6 and 0), while an ablation showed that access to structured in-house evidence increased mean AUC by 34%.
The study presents Andromeda 2, an agentic system that reasons over structured in-house experimental evidence and invokes computational and experimental tools, achieving a 50% high-AUC hit rate for paclitaxel self-emulsifying drug delivery system (SEDDS) development at a matched budget of 96 formulations (versus 17% for Andromeda 1 and 2% for wet-lab DoE) and identifying 12 formulations meeting all four target product profile (TPP) objectives (versus 6 and 0), while an ablation showed that access to structured in-house evidence increased mean AUC by 34%.
The study presents Andromeda 2, an agentic system that reasons over structured in-house experimental evidence and invokes computational and experimental tools, achieving a 50% high-AUC hit rate for paclitaxel self-emulsifying drug delivery system (SEDDS) development at a matched budget of 96 formulations (versus 17% for Andromeda 1 and 2% for wet-lab DoE) and identifying 12 formulations meeting all four target product profile (TPP) objectives (versus 6 and 0), while an ablation showed that access to structured in-house evidence increased mean AUC by 34%.
The study presents Andromeda 2, an agentic system that reasons over structured in-house experimental evidence and invokes computational and experimental tools, achieving a 50% high-AUC hit rate for paclitaxel self-emulsifying drug delivery system (SEDDS) development at a matched budget of 96 formulations (versus 17% for Andromeda 1 and 2% for wet-lab DoE) and identifying 12 formulations meeting all four target product profile (TPP) objectives (versus 6 and 0), while an ablation showed that access to structured in-house evidence increased mean AUC by 34%.